Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2− Metastatic Breast Cancer Who Have Received … Ended

2022-502593-17-00 Locally advanced or metastatic hormone receptor (HR)-po 5 2023-09-19
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer. Ended

2022-502738-18-00 Metastatic Non-small Cell Lung Cancer 4 2023-09-15
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients with Hormone Recepto… Ended

2022-502322-41-00 Metastatic breast cancer 5 2023-09-12
Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841) Ended

2022-500100-21-01 Follicular lymphoma 4 2023-09-11
Perioperative/Adjuvant atezolizumab in patients with MSI-high or MMRdeficient stage II high risk or stage III colorectal cancer ineligible f… Ended

2024-515224-37-00 Patients with MSI-high or MMR-deficient stage III color 4 2023-08-29
A phase 3 study to Evaluate the Efficacy and Safety of HLX10 or placebo in Combination With Chemotherapy and Radiotherapy in Patients With L… Ended

2024-515047-31-00 Patients with Limited-Stage Small Cell Lung Cancer (LS- 5 2023-08-28
The PRESTO Trial - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early… Ended

2024-512980-29-00 T1-T2N0 esophageal adenocarcinoma including gastroesoph 4 2023-08-28
A Phase 1b study to evaluate the safety, pharmacokinetics, and anti-tumour activity of the Myc inhibitor OMO-103 administered intravenously … Ended

2023-504376-21-00 pancreatic ductal adenocarcinoma 3 2023-08-28
A study to test different doses of obrixtamig (BI 764532) combined with ezabenlimab in patients with Small Cell Lung Carcinoma and other neu… Ended

2022-502728-30-00 Small Cell Lung Carcinoma expressing DLL3 3 2023-08-25
SUrGery with or without dARolutamide in high-risk and/or locally advanced prostate cancer Ended

2022-501518-67-00 High-risk and/or locally advanced prostate cancer 4 2023-08-10
A study to evaluate the dose optimization measures and safety of Etentamig (ABBV-383) in subjects with Relapsed or Refractory Multiple Myelo… Ended

2023-504674-38-00 Relapsed or Refractory Multiple Myeloma 3 2023-07-31
An open, randomised, controlled phase II trial of CellProtect in combination with Isatuximab antibody versus Isatuximab antibody alone as ma… Ended

2024-514527-42-00 Multiple myeloma 4 2023-07-28
A study of LOXO-783 in Patients with PIK3CA H1047R-Mutant Advanced Breast Cancer and Other Solid Tumors. Ended

2023-509568-81-00 Advanced Breast Cancer and Other Solid Tumors 1 2023-07-27
Phase II, Multicenter Study to Assess Safety and Efficacy of Combination of Sargramostim with D-VCd Therapy (Daratumumab, Cyclophosphamide, … Ended

2024-518658-18-00 Light chain amyloidosis (AL amyloidosis) is an incurabl 4 2023-07-26
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
A multi-center Phase 2 study of neoadjuvant immunotherapy in combination with the anti-GDF-15 antibody visugromab (CTL-002) for the treatmen… Ended

2024-513957-55-00 Muscle invasive bladder cancer set to undergo radical c 4 2023-07-21
Phase I study of AZD9592 in solid tumors Ended

2022-501570-18-00 Recurrent or metastatic Head and NeckSquamous Cell Carc 1 2023-07-18
Phase II study evaluating the efficacy and safety of preoperative immunotherapy (pembrolizumab with eftilagimod alfa) in combination with ra… Ended

2024-515971-37-00 Resectable soft tissue sarcomas 4 2023-07-17
Master Protocol of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobilia… Ended

2022-502317-29-00 Advanced Hepatobiliary Cancer 4 2023-07-12
A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com… Ended

2022-501576-25-00 Melanoma 5 2023-07-07
PaTcH Trial: A phase 2 study to explore primary and emerging resistance mechanisms in patients with metastatic refractory Pancreatic cancer … Ended

2024-513429-21-00 Metastatic refractory Pancreatic Cancer 4 2023-06-27
A STUDY TO INVESTIGATE THE SAFETY AND EFFECTIVENESS OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY FOR PATIENTS WITH NON-SMALL CEL… Ended

2022-502977-41-00 Non-Small Cell Lung Cancer 5 2023-06-23
A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of belantamab mafodotin administered in comb… Ended

2024-517723-39-00 Newly diagnosed patients with multiple myeloma 4 2023-06-23
Single-center phase II study on the use of electrochemotherapy in the treatment of Paget's disease and high-grade or initially invasive prec… Ended

2024-518796-65-00 patients with newly diagnosed or recurrent high-grade o 4 2023-06-17